Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Einstein (São Paulo) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404 |
Resumo: | ABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms. |
id |
IIEPAE-1_901ebee6d620fd8e395f1959e9dc2464 |
---|---|
oai_identifier_str |
oai:scielo:S1679-45082010000400404 |
network_acronym_str |
IIEPAE-1 |
network_name_str |
Einstein (São Paulo) |
repository_id_str |
|
spelling |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient ratsGuanylate cyclaseNitric oxideUrinary bladder, overactiveRatsABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms.Instituto Israelita de Ensino e Pesquisa Albert Einstein2010-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404einstein (São Paulo) v.8 n.4 2010reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.1590/s1679-45082010ao1789info:eu-repo/semantics/openAccessD'Ancona,Carlos Arturo LeviMónica,Fabíola Zakia TauficReges,RicardoCohen,DavidSilva,Fabio Henrique daNucci,Gilberto DeAntunes,Edsoneng2017-03-14T00:00:00Zoai:scielo:S1679-45082010000400404Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2017-03-14T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false |
dc.title.none.fl_str_mv |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
title |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
spellingShingle |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats D'Ancona,Carlos Arturo Levi Guanylate cyclase Nitric oxide Urinary bladder, overactive Rats |
title_short |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
title_full |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
title_fullStr |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
title_full_unstemmed |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
title_sort |
Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats |
author |
D'Ancona,Carlos Arturo Levi |
author_facet |
D'Ancona,Carlos Arturo Levi Mónica,Fabíola Zakia Taufic Reges,Ricardo Cohen,David Silva,Fabio Henrique da Nucci,Gilberto De Antunes,Edson |
author_role |
author |
author2 |
Mónica,Fabíola Zakia Taufic Reges,Ricardo Cohen,David Silva,Fabio Henrique da Nucci,Gilberto De Antunes,Edson |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
D'Ancona,Carlos Arturo Levi Mónica,Fabíola Zakia Taufic Reges,Ricardo Cohen,David Silva,Fabio Henrique da Nucci,Gilberto De Antunes,Edson |
dc.subject.por.fl_str_mv |
Guanylate cyclase Nitric oxide Urinary bladder, overactive Rats |
topic |
Guanylate cyclase Nitric oxide Urinary bladder, overactive Rats |
description |
ABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/s1679-45082010ao1789 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Israelita de Ensino e Pesquisa Albert Einstein |
publisher.none.fl_str_mv |
Instituto Israelita de Ensino e Pesquisa Albert Einstein |
dc.source.none.fl_str_mv |
einstein (São Paulo) v.8 n.4 2010 reponame:Einstein (São Paulo) instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) instacron:IIEPAE |
instname_str |
Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) |
instacron_str |
IIEPAE |
institution |
IIEPAE |
reponame_str |
Einstein (São Paulo) |
collection |
Einstein (São Paulo) |
repository.name.fl_str_mv |
Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE) |
repository.mail.fl_str_mv |
||revista@einstein.br |
_version_ |
1752129905864212480 |